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Introduction. Controversy continues over the appropriate timing of sentinel lymph node (SLN) biopsy in locally advanced breast
cancer (LABC) patients receiving neoadjuvant chemotherapy. We evaluated the feasibility and accuracy of SLN biopsy in LABC
patients with cytology-proven axillary nodal metastasis who become clinically node-negative after neoadjuvant chemotherapy.
Materials. 30 consecutive patients with LABC, who had become clinically node-negative after 3 cycles of neoadjuvant chemo-
therapy, were included in the study. They were then subjected to SLN biopsy, axillary lymph node dissection, and breast surgery.
Results. Sentinel nodes were successfully identiﬁed in 26 of the 30 patients, resulting in an identiﬁcation rate of 86.67%, sensitivity
of 83.33%, false negative rate of 20%, negative predictive value of 72.73%, and an overall accuracy of 88.46%. No complications
were observed as a result of dye injection. Conclusions. SLN biopsy is feasible and safe in LABC patients with cytology-positive
nodes who become clinically node-negative after neoadjuvant chemotherapy. Our accuracy rate, identiﬁcation rate, and false neg-
ative rate are comparable to those in node-negative LABC patients. SLN biopsy as a therapeutic option in LABC after neoadjuvant
chemotherapy is a promising option which should be further investigated.
1.Introduction
Prognosis in patients with breast cancer depends mainly on
the extent of lymph node involvement, size of the tumor, and
the histological grade of the tumor. Among these factors,
axillary lymph node status is regarded as the single best
marker of prognosis [1, 2].
For axillary nodal involvement, treatment in the form of
level I and II axillary lymph node dissection (ALND) is con-
sidered optimum. But it is also associated with a number of
complications including self-limiting complaints of numb-
ness (70%), pain (33%), weakness (25%), swelling (24%),
and stiﬀness (15%) which can interfere with daily living in
upto 39% of cases. The risk of arm edema varies from 8% to
37% being related to the level of dissection and the number
of nodes removed. Axillary vein thrombosis and injury tothe
motor nerves of axilla are extremely uncommon [2, 3].
Following the introduction of sentinel lymph node
(SLN) biopsy for breast cancer, this technique has been
widely adopted by cancer centers around the world for node-
negative early breast cancer [2]. If the sentinel lymph node
(SLN)isnegative,thelikelihoodforotherlymphnodesinthe
axilla to be negative ranges from 95 to 100%. So unnecessary
ALND can be avoided in patients with negative axillae, and
the associated morbidity of ALND can be reduced [4].
Neoadjuvant chemotherapy can reduce tumor size and
downstage the primary tumor. Several studies could demon-
strate a signiﬁcant reduction in tumor size and a signiﬁcant
increase in breast-conserving surgery in operable breast can-
cer [5, 6]. Response to treatment is also an excellent indi-
cator of chemotherapy eﬀectiveness [5, 7–9]. In locally
advanced breast cancer (LABC), treatment typically includes
neoadjuvant chemotherapy, surgery, and radiation therapy
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Controversy continues over the appropriate timing of
SLN biopsy in LABC patients receiving neoadjuvant chemo-
therapy as it could oﬀer them the potential beneﬁt of axillary
downstaging and avoidance of axillary dissection. Recently,
it has been shown that in locally advanced breast cancer,
patients with a complete pathologic axillary response had
a signiﬁcantly higher overall survival than patients with re-
sidual disease [10]. Their study validated the prognostic
stratiﬁcationofpatientswithacompletepathologicalaxillary
response to neoadjuvant chemotherapy.
The aim of this study was to evaluate the feasibility and
accuracy of SLN biopsy in locally advanced breast cancer
patients with cytology-proven axillary nodal metastasis who
become clinically node-negative after neoadjuvant chemo-
therapy.
2.MaterialsandMethods
The present prospective observational study was conducted
by the Departments of Surgery and Pathology at Lady Hard-
inge Medical College, New Delhi.
A total of 30 consecutive patients (accrued over a period
of 18 months) with cytology/biopsy-proven locally advanced
breast cancer LABC (AJCC Stage III) and cytology-proven
axillary nodal metastasis, who became clinically node-neg-
ative (on clinical examination) after neoadjuvant chemo-
therapy, were included in the study. Patients who had prior
axillary surgery and those with inﬂammatory breast cancer
were excluded from the study. The study was cleared by the
Institutional Ethics Committee. Informed consent was taken
from all the patients for the planned procedure.
All patients were subjected to a detailed clinical evalu-
ation, routine investigations, and metastatic workup at the
time of presentation. Investigations included a complete
hemogram, blood sugar, liver function tests, kidney function
tests, ECG, echocardiogram, chest X-ray, an ultrasound of
theabdomen,andabonescan.Breastinvestigationsincluded
a mammogram, breast ultrasound, cytology, and trucut
biopsy for ER/PR/Her2 status. Breast ultrasound was used to
deﬁneclinicalresponseofthebreasttumortochemotherapy.
The patients were given three cycles of neoadjuvant
chemotherapy (CAF: cyclophosphamide 600mg/m2, adri-
amycin 50mg/m2, 5-ﬂurouracil 600mg/m2), and patients
who satisﬁed the inclusion criteria were subjected to sentinel
node biopsy, axillary lymph node dissection, and breast sur-
gery. All patients were operated by the same consultant.
After the administration of anesthesia, the planned inci-
sionwasmarkedbyamarkingpencilontheskinofthebreast
containing tumor. 2 to 5mL of sterile 1% isosulphan blue
(Patent Blue) dye was injected peritumourally (upper outer
aspect of tumor) using a syringe and a 22G needle. This
was followed by a breast massage for 10 minutes. Incision
was made just below the axillary hairline. The incision
was planned in such a way as to be included in the mas-
tectomy incision in patients undergoing modiﬁed radical
mastectomy. Dissection was rapidly done in the axilla to
the clavipectoral fascia, and on reaching the fascia, the blue
stained lymphatic(s) was carefully identiﬁed and traced up
to the blue sentinel node(s). Sentinel node(s) was identiﬁed
by its blue stain. Sentinel node(s) was then harvested before
performing the breast surgery. Standard axillary dissection
(ALND) was then performed removing level I and II axillary
lymph nodes. Lymph nodes removed during ALND were
labeled as nonsentinel nodes (NSN). Patients were observed
for any immediate or late complications associated with dye
injection.
Forthepurposeofhistopathologicalexamination(which
included cytokeratin immunohistochemistry), sentinel node
and nonsentinel nodes were submitted separately for histo-
pathological analysis. In cases where more than one sentinel
node was found, each node was analyzed as sentinel node.
A standardized set of data was abstracted from each pa-
tient. Data collection from all the patients was then ana-
lyzed using SPSS statistical software (version 9.0; SPSS Inc,
Chicago, ILL, USA).
3. Observations andResults
The study group comprised of 30 consecutive patients of
locally advanced breast cancer (AJCC Stage III) with cytolo-
gy-proven axillary lymphadenopathy at presentation who
became clinically node-negative (on clinical examination)
after completion of three cycles of neoadjuvant chemother-
apy. These patients were then subjected to sentinel lymph
node biopsy followed by axillary lymph node dissection at
the same operation. Out of these 30 patients, 29 patients
underwent modiﬁed radical mastectomy while one patient
had breast conserving surgery done.
In the present study, the mean age of the patients was
49.45 years (range from 25 to 65 years, median age 45 years).
All the patients in the present study were females. Out of the
30 patients, 9 (30%) were premenopausal, while 21 (70%)
were postmenopausal. None of the patients had a family
history of breast, colon, ovary, or any other cancer. 60%
(18/30) of patients had primary tumor in the left breast,
while 40% (12/20) patients had tumor in the right breast.
The size of the primary tumor varied from 3cm to 7.5cm
(T2, T3, and T4b).
All the 30 patients had inﬁltrating ductal cancer, out of
whic h1wasw elldiﬀerentiated(grade1),21weremoderately
diﬀerentiated (grade 2), and the remaining 8 were poorly
diﬀerentiated (grade 3). 14 patients were estrogen receptor
positive, 12 were progesterone receptor positive, and 11 pa-
tients had Her2 overexpression.
Out of these 30 patients, minimal response (less than
50% reduction in size) to neoadjuvant chemotherapy was
seen in 14 patients (46.67%), partial response (more than
50% reduction in size) was seen in 14 patients (46.67%), and
complete response was seen in the remaining 2 patients
(6.67%). Breast ultrasound was used to deﬁne clinical re-
sponse of the breast tumor to chemotherapy.
Out of the total of 30 patients who underwent SLN
biopsyinthepresentstudy,thesentinelnodewassuccessfully
identiﬁedin26patients.Sentinelnodeidentiﬁcationratewas
86.67%. The number of sentinel nodes removed per patient
ranged from 1 to 4 (1(n = 18), 2(n = 8), 3(n = 3), 4(n = 1)).
Average number of sentinel node identiﬁed per patient wasInternational Journal of Breast Cancer 3
Table 1:Tumormetastasisinsentinelandnonsentinellymphnodes
in patients after neoadjuvant chemotherapy when sentinel nodes
were successfully identiﬁed (n = 26).
Non-sentinel
node with
metastasis
Non-sentinel
node without
metastasis
Total
Sentinel node with
metastasis 1 231 5
Sentinel node
without metastasis 38 1 1
T o t a l 1 51 12 6
1.57. In most of the patients, sentinel node identiﬁed was 1
in number.
The number of nonsentinel nodes (NSN) identiﬁed
ranged from 9 to 19. Average number of nonsentinel node
identiﬁed after ALND was 13.5. Median number of NSN
identiﬁed was 13.
Out of the total 26 cases in which a sentinel node was
identiﬁed, the sentinel node was positive for tumor metasta-
sisin15cases,therestwerenegativeonhistopathology.Inthe
15 cases when the sentinel node was positive for metastasis,
the nonsentinel nodes were positive for tumor metastasis in
12 cases. In the rest 3 cases in which the sentinel node was
positive, the nonsentinel nodes were found to be negative for
tumormetastasisonhistopathology(Table 1).Itappearsthat
in these 3 patients, the sentinel nodes were the only involved
nodes.
Out of the 11 cases when the sentinel node was negative
for metastasis, in 8 cases the nonsentinel nodes were also
negativefortumormetastasisonhistopathology,whileinthe
remaining 3 cases, the nonsentinel nodes were positive for
tumor metastasis, thereby accounting for 3 false negatives in
the study (Table 1). Out of these 3 patients, 2 had only one
non-sentinel node positive for tumor, while the third had 2
non-sentinel nodes showing tumor. It is possible that ﬁbrosis
around the involved nodes could have resulted in the false
negatives.
Thus in our study, sentinel node dissection was at-
temptedin 30patients, outofwhichsentinel nodes weresuc-
cessfully identiﬁed in 26 patients, with a sentinel node
identiﬁcation rate of 86.67%. We achieved a sensitivity of
83.33% (15/18), false negative rate of 20% (3/15), a negative
predictive value of 72.73% (8/11), and an overall accuracy of
88.46% (23/26).
No complications were observed as a result of dye injec-
tion in any of the patients. All of the patients had a bluish
green discoloration of the body (especially the face) and
observedgreen-coloredurinefor12to24hoursaftersurgery .
4. Discussion
Although the impact of resecting axillary lymph nodes on
survival is currently a subject of controversy, accurate assess-
ment of axillary nodal status provides the most important
prognostic information for patients with primary breast
cancer. It also directs selection of adjuvant systemic therapy
and reduces the risk of regional recurrence of breast cancer
in the axilla [2, 11, 12].
Following the introduction of sentinel lymph node
(SLN) biopsy for early breast cancer, this technique has been
widely adopted by cancer centers around the world. If the
SLN is negative, the likelihood for other lymph nodes in the
axilla to be negative ranges from 95 to 100%. So unnecessary
axillary lymph node dissection (ALND) can be avoided, and
its attendant morbidity can be reduced, in many patients
with small breast cancers and negative axillae [4, 13–16].
Most of the reported experience with SLN biopsy
includes patients with clinical stage T1-2 N0 [17]. Locally
advanced breast cancer was also considered as one of the
contraindications. However, recent studies have now shown
that SLN biopsy can be considered if axillary lymph nodes
are negative for metastases even in locally advanced breast
cancer [10, 18, 19].
Neoadjuvant chemotherapy has become the standard of
careforthetreatmentofpatientswithlocallyadvancedbreast
cancer and has also been prospectively evaluated in patients
with earlier-stage disease [20–23]. Neoadjuvant chemother-
apy allows for individual in vivo assessment of primary
tumor and metastatic lymph node response to chemo-
therapy. In addition, although chemotherapy is primarily
thought of as important in eradicating occult distant disease,
it can have a signiﬁcant eﬀect on locoregional disease as well.
Tumor downstaging with neoadjuvant chemotherapy can
convert inoperable disease to operable disease and can allow
breast-conserving surgery in patients for whom mastectomy
is initially the only option for control of locoregional disease
[23–25].
During their study in locally advanced cases, Kuerer et al.
concluded that neoadjuvant chemotherapy can completely
clear the axilla of microscopic disease before surgery, and
occult metastases (Isolated Tumor Cells-AJCC pN0(I+))
were found in only 10% of patients with a histologically neg-
ative axilla (AJCC pN0: No regional lymph node metastasis
histologically). The results of their study have implications
for the potential use of sentinel lymph node biopsy as
an alternative to axillary dissection in patients treated with
neoadjuvant chemotherapy. Their ﬁnding that only 10%
of patients with complete axillary conversion (histologically
negative axilla) have occult nodal metastases suggests that
SLN biopsy may be appropriate in patients whose disease is
downstaged with neoadjuvant chemotherapy [9].
Cox et al. [10] reported on a series of 89 patients with
locally advanced breast cancer subjected to SLN biopsy
before neoadjuvant chemotherapy. 27% of their patients had
a complete pathologic axillary response; these patients had a
signiﬁcantly higher overall survival than patients with resid-
ualdisease.Theirstudyvalidatedtheprognosticstratiﬁcation
of patients with a complete pathological axillary response to
neoadjuvant chemotherapy.
During the last few years, there have been a number of
clinical trials on the eﬀectiveness and role of SLN biopsy in
patients after preoperative chemotherapy, mainly in early-
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A retrospective analysis of 428 of 2,365 patients in the
NSABP 27 trial who received chemotherapy followed by
sentinel node biopsy and an axillary dissection was done
[26]. 2,411 patients were randomly assigned to NSABP Pro-
tocol B-27. In the 2,365 patients (98.1%) for whom operative
andpathologyreportswereavailable,therewere428(18.1%)
who had lymphatic mapping and for whom an attempt was
made to identify and remove a sentinel node. There were
signiﬁcant diﬀerences in the distribution of some of the
patient and tumor characteristics between the group of
patients who had an SLN biopsy attempted and the group
of 1,937 patients (81.9%) who did not. Patients in whom
an SLN biopsy was attempted had smaller tumors and
clinically uninvolved axillary nodes and are more likely to
be lumpectomy candidates. Of the 428 patients in whom
lymphatic mapping was attempted, at least one sentinel node
was identiﬁed and removed in 363. Of the 363 patients in
whom at least one sentinel node was identiﬁed and removed,
20 patients (5.5%) did not have the required axillary node
dissection, leaving 343 patients in whom the accuracy of the
sentinel node in correctly staging the axilla could be assessed.
BecauseSLNbiopsywasnotmandatedinthestudy,therewas
no predeﬁned protocol dictating the method of lymphatic
mapping or the approach to SLN biopsy. In the majority of
the cases, nodal positivity was determined by hematoxylin
and eosin staining only. However, in a handful of cases,
additional immunohistochemical staining was performed to
further evaluate the status of sentinel nodes. The analysis of
thesecasesdemonstratedan85%sentinelnodeidentiﬁcation
rate and a false-negative rate of 11%, which are similar to
those observed in patients undergoing an initial sentinel
node biopsy during the same period [26].
Xing et al. in 2006 [27] conducted a meta-analysis of
twenty-one studies (total of 1273 patients) that examined
the results of SLN biopsy after chemotherapy. The sensitivity
of SLN biopsy in the individual studies ranged from 67 to
100 percent, the negative predictive value ranged from 56 to
100 percent, and the overall accuracy ranged from 77 to 100
percent. However, the majority of patients in these studies
had stage II breast cancer with negative axillary nodes at
presentation.
The ongoing ACOSOG Z1071 trial “A Phase II study of
sentinel lymph node surgery and axillary lymph node dis-
sectionfollowingneoadjuvantchemotherapyinwomenwith
stage II-IIIB node-positive breast cancer” attempts to deter-
mine the false negative rate for sentinel lymph node (SLN)
surgeryinwomenwithnode-positivebreastcancerwhohave
completed or plan to undergo neoadjuvant chemotherapy.
However, this study includes both stage II and III breast
cancer and also includes patients who are node positive after
completing the chemotherapy. The trial is expected to be
completed by end 2013 [28].
StudiesonthefeasibilityandaccuracyofSLNbiopsyafter
preoperative chemotherapy in locally advanced breast cancer
patients with documented axillary metastasis are few and the
results are inconclusive.
Shen et al. [29] studied 69 patients with cytology-con-
ﬁrmed axillary metastasis who underwent SLN biopsy after
chemotherapy. However, out of these, only 23 were LABC
(AJCC stage III). The overall SLN identiﬁcation rate was
92.8%, and a false negative rate of 25%. They concluded that
the status of the SLN cannot be used as a reliable indicator of
the presence or absence of residual disease in the axilla in this
patient population. Newman et al. [30]e v a l u a t e d5 4b r e a s t
cancer patients with biopsy-proven axillary nodal metastasis.
The SLN identiﬁcation rate after delivery of neoadjuvant
chemotherapy was 98%, with a false negative rate of 8.6%.
They concluded that SLN biopsy after neoadjuvant chemo-
therapyinpatientswithdocumentednodaldiseaseatpresen-
tation accurately identiﬁed cases that may have been down-
staged to node-negative status and can spare this subset of
patients from the morbidity of an ALND. Another recent
study from Korea [31] concluded that SLN identiﬁcation
rate, but not accuracy, is signiﬁcantly decreased after preop-
erative chemotherapy in axillary node-positive breast cancer
patients. They also suggested that for patients who achieve
complete axillary clearance by chemotherapy, SLN biopsy
could replace ALND.
In the present study, although having a small sample size,
we have showed that SLN biopsy is feasible and safe in locally
advanced carcinoma breast who become clinically node-
negativeafterneoadjuvantchemotherapy.Ouraccuracyrate,
identiﬁcation rate, and false negative rate are comparable
to reports in the literature in node-negative LABC patients
after chemotherapy. Blue dye method is a safe procedure and
none of the patients developed any complications of the dye
injection.
LABC consists of a heterogeneous group of patients
falling in AJCC stage III. Having advanced stage disease, they
have a poor prognosis. However, even in this group, the
subgroup of LABC patients in whom there is a complete
axillary response to neoadjuvant chemotherapy have a good
prognosis—havingshowntohaveasigniﬁcantlyhigherover-
all survival than patients with residual disease [9]. Identi-
ﬁcation of this subgroup of LABC patients can help target
treatment modalities for improved outcomes.
Most of the studies in the literature on SLN biopsy after
neoadjuvant chemotherapy involved earlier stage disease,
smaller tumors, with negative nodes at presentation. Our
study focuses on the likely feasibility and role of SLN biopsy
inthisgood prognosis subgroupofLABCpatients withcom-
plete axillary response to neoadjuvant chemotherapy. Addi-
tional studies are needed to answer the on-going debate
regarding optimal treatment of the axilla in LABC patients
who are rendered clinically node-negative after neoadjuvant
treatment. Following neoadjuvant therapy, accurate evalua-
tion of the axilla by SLN biopsy is feasible in these patients.
Sentinel lymph node biopsy as a therapeutic option in locally
advanced breast cancer patients who become clinically node-
negative after neoadjuvant chemotherapy is a promising
option that can spare axillary dissection and its morbidity,
and which should be further investigated.
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